Skip to main content
Addgene

pcDNA3-ALK3 K261R
(Plasmid #80875)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 80875 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pcDNA3
  • Vector type
    Mammalian Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    ALK3
  • Alt name
    BMPR1A
  • Alt name
    bone morphogenetic protein receptor type 1A
  • Species
    H. sapiens (human)
  • Mutation
    K261R (Kinase inactive)
  • Entrez Gene
    BMPR1A (a.k.a. 10q23del, ACVRLK3, ALK-3, ALK3, BMPR-1A, CD292, SKR5)
  • Promoter CMV
  • Tag / Fusion Protein
    • HA (C terminal on backbone)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site EcoRI (not destroyed)
  • 3′ cloning site XhoI (not destroyed)
  • 5′ sequencing primer CMV-F
  • 3′ sequencing primer BGH-rev
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

This plasmid contains a P2A mutation compared to NM_004329.2 and SL insertion after the c-terminal HA tag. The depositor states that these discrepancies do not affect plasmid function.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pcDNA3-ALK3 K261R was a gift from Aristidis Moustakas (Addgene plasmid # 80875 ; http://n2t.net/addgene:80875 ; RRID:Addgene_80875)
  • For your References section:

    The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling. Raja E, Tzavlaki K, Vuilleumier R, Edlund K, Kahata K, Zieba A, Moren A, Watanabe Y, Voytyuk I, Botling J, Soderberg O, Micke P, Pyrowolakis G, Heldin CH, Moustakas A. Oncotarget. 2016 Jan 12;7(2):1120-43. doi: 10.18632/oncotarget.6683. 10.18632/oncotarget.6683 PubMed 26701726